These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 30185395)

  • 21. Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.
    Bourlière M; Gordon SC; Schiff ER; Tran TT; Ravendhran N; Landis CS; Hyland RH; Stamm LM; Zhang J; Dvory-Sobol H; Subramanian GM; Brainard DM; McHutchison JG; Serfaty L; Thompson AJ; Sepe TE; Curry MP; Reddy KR; Manns MP
    Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):559-565. PubMed ID: 29859740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.
    Balistreri WF; Murray KF; Rosenthal P; Bansal S; Lin CH; Kersey K; Massetto B; Zhu Y; Kanwar B; German P; Svarovskaia E; Brainard DM; Wen J; Gonzalez-Peralta RP; Jonas MM; Schwarz K
    Hepatology; 2017 Aug; 66(2):371-378. PubMed ID: 27997679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report.
    Smolders EJ; Willemse SB; El-Sherif O; Khoo S; Burger DM
    Ann Hepatol; 2018; 17(3):525-529. PubMed ID: 29735803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study.
    Li H; Butler K; Yang L; Yang Z; Teng R
    Clin Drug Investig; 2012 Feb; 32(2):87-97. PubMed ID: 22168538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.
    Desnoyer A; Pospai D; Lê MP; Gervais A; Heurgué-Berlot A; Laradi A; Harent S; Pinto A; Salmon D; Hillaire S; Fontaine H; Zucman D; Simonpoli AM; Muret P; Larrouy L; Bernard Chabert B; Descamps D; Yazdanpanah Y; Peytavin G
    J Hepatol; 2016 Jul; 65(1):40-47. PubMed ID: 26952005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection.
    Wirth S; Rosenthal P; Gonzalez-Peralta RP; Jonas MM; Balistreri WF; Lin CH; Hardikar W; Kersey K; Massetto B; Kanwar B; Brainard DM; Shao J; Svarovskaia E; Kirby B; Arnon R; Murray KF; Schwarz KB
    Hepatology; 2017 Oct; 66(4):1102-1110. PubMed ID: 28543053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects.
    Denning J; Cornpropst M; Flach SD; Berrey MM; Symonds WT
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1201-8. PubMed ID: 23262999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.
    Gane EJ; Kowdley KV; Pound D; Stedman CA; Davis M; Etzkorn K; Gordon SC; Bernstein D; Everson G; Rodriguez-Torres M; Tsai N; Khalid O; Yang JC; Lu S; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Tong M; Chung RT; Beavers K; Poulos JE; Kwo PY; Nguyen MH
    Gastroenterology; 2016 Nov; 151(5):902-909. PubMed ID: 27486033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single- and multiple-dose pharmacokinetics of the peripheral non-narcotic antitussive moguisteine in healthy Chinese volunteers.
    Gou ZP; Zheng L; Wang Y; Feng P; Xiang J
    Eur J Pharm Sci; 2019 Mar; 130():166-172. PubMed ID: 30703444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and tolerability of Tenofovir disoproxil fumarate 300 mg once daily: an open-label, single- and multiple-dose study in healthy Chinese subjects.
    Hu CY; Liu YM; Liu Y; Chen Q; Wang W; Wu K; Dong J; Li J; Jia JY; Lu C; Sun SX; Yu C; Li X
    Clin Ther; 2013 Dec; 35(12):1884-9. PubMed ID: 24148552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial.
    Gupta N; Manirambona L; Shumbusho F; Kabihizi J; Murangwa A; Serumondo J; Makuza JD; Nsanzimana S; Muvunyi CM; Mukabatsinda C; Musabeyezu E; Camus G; Grant PM; Kateera F
    Lancet Gastroenterol Hepatol; 2022 Jun; 7(6):542-551. PubMed ID: 35248212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sofosbuvir/velpatasvir fixed-dose combination for the treatment of chronic hepatitis C virus infection.
    Nehra V; Rizza SA; Temesgen Z
    Drugs Today (Barc); 2017 Mar; 53(3):177-189. PubMed ID: 28447075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sofosbuvir for the treatment of chronic hepatitis C virus infection.
    Temesgen Z; Talwani R; Rizza SA
    Drugs Today (Barc); 2014 Jun; 50(6):421-34. PubMed ID: 24983590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
    García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
    Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear).
    Lawitz EJ; Rodriguez-Torres M; Denning J; Mathias A; Mo H; Gao B; Cornpropst MT; Berrey MM; Symonds WT
    J Viral Hepat; 2013 Oct; 20(10):699-707. PubMed ID: 24010644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
    Lawitz E; Reau N; Hinestrosa F; Rabinovitz M; Schiff E; Sheikh A; Younes Z; Herring R; Reddy KR; Tran T; Bennett M; Nahass R; Yang JC; Lu S; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Pearlman B; Shiffman M; Hawkins T; Curry M; Jacobson I
    Gastroenterology; 2016 Nov; 151(5):893-901.e1. PubMed ID: 27486034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, Tolerability and Pharmacokinetics of Yimitasvir Phosphate Capsule, a Novel Oral Hepatitis C Virus NS5A Inhibitor, in Healthy Chinese Volunteers.
    Zhao N; Xie R; Zhao X; Zhao H; Jia B; Zhang Y; Luo L; Huang Z; Li J; Wang X; Yan H; He B; Xie H; Ren Q; Cui Y
    Clin Drug Investig; 2019 Jul; 39(7):671-681. PubMed ID: 31079356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection.
    Lawitz E; Rodriguez-Torres M; Denning JM; Albanis E; Cornpropst M; Berrey MM; Symonds WT
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1209-17. PubMed ID: 23263000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons.
    Mastrorosa I; Tempestilli M; Notari S; Lorenzini P; Fabbri G; Grilli E; Bellagamba R; Vergori A; Cicalini S; Ammassari A; Agrati C; Antinori A
    Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):135-142. PubMed ID: 34623616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry.
    Ruane PJ; Ain D; Stryker R; Meshrekey R; Soliman M; Wolfe PR; Riad J; Mikhail S; Kersey K; Jiang D; Massetto B; Doehle B; Kirby BJ; Knox SJ; McHutchison JG; Symonds WT
    J Hepatol; 2015 May; 62(5):1040-6. PubMed ID: 25450208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.